|
|
 |
|
Viewing report
|
|
|
|
Mastering Biomarkers: Five Top Diagnostics Companies to Watch
Decision Resources, Inc., June 2010, Pages: 29
Measuring the success of a diagnostics company is dependent on product, technology, and business model. Some companies - we have identified five top players in the industry - have managed to achieve favourable results by embracing strategies that have enabled them to win on all three fronts. These companies are at the core of industry growth because of their unparalleled strategic decision making, product offerings, market and product diversification, standards setting, efficiency creation, and partnering activity. They have demonstrated the ability to design and execute business strategies that we believe offer lessons to other IVD companies focusing on molecular diagnostics and biomarkers as they pursue growth opportunities in 2010 and beyond.
Questions answered in this report:
- Diagnostics companies employ various strategies to ensure the success of their businesses - from relying on predominantly organic development, to a pipeline that includes products from a mix of organic and licensed/ acquired technologies, to relying solely on new products through acquisitions. What strategies dominate the business models of the five top companies we have identified in this report? In what ways have the companies put into practice their strategic models?
- The value of the IVD market in 2009 was nearly $30 billion, and it is estimated to reach $50 billion in 2012. Where do the revenues of the five companies lie in this forecast? Which company has held the highest revenue values and which has had the highest compound annual growth rate?
- Each of the companies we identified differs in size and offers a mix of products and services. However, certain themes are consistent across their successes and strategies. What are the key similarities and differences among these companies? What lessons can be drawn from the challenges they have faced and successes they have achieved?
Scope of the report:
- Diagnostics companies: Using a methodology that considers revenue and market potential based on current company strategy, we identify five top companies that should be monitored for further innovation and dealmaking trends: Inverness Medical Solutions, Qiagen, Illumina, Gen-Probe, and Genomic Health.
- Dealmaking assessment: Analysis of at least 50 acquisitions from January 2002 to April 2010.
- Market forecast features: Using Decision Resources’ Pharmaview analysis, we provide company revenues (2004-2009) for our five top diagnostics companies to watch.
- Lessons learned: Based on the key successes achieved by the five companies, we distill the main lessons learned for biopharmaceutical companies looking to invest in biomarker-based sequencing or molecular diagnostics companies or for diagnostics companies aiming to grow their own capabilities.
Key terms for this report:
Acquisitions, Array, Automation, Biomarkers, Cardiovascular diagnostics, Diagnostics, Genomics, Infectious disease testing, Molecular diagnostics, Multiplexing, Next-generation sequencing (NGS), Point-of-care testing (POC; POCT), Proteomics, Rapid testing
Customers who bought this item also bought
DNA Sequencing - Technologies, Markets and Companies
Personalized Medicine: Companies, Trends and World Market
Biomarkers, Tests and Trends for Drug R&D
Polymerase Chain Reaction (PCR): Products/Tools - A Global Market Watch, 2009-2015
Outlook of China Genomics and Proteomics Market - Application in Molecular Biomarker, Diagnostics and Personalized Medicine
Polymerase Chain Reaction (PCR) In Medical Application - An Analytical Report, 2009-2015
Driving Drug and Diagnostic R&D: The Undeniable Influence of Biomarkers
Biomarkers - Technologies, Markets and Companies
Cytogenetics - Technologies, Markets and Companies
Biochips and Microarrays - Technologies, Markets and Companies
|
|
|
|
